This page shows the latest molnupiravir news and features for those working in and with pharma, biotech and healthcare.
Merck &Co – known as MSD outside the US and Canada – and Ridgeback Biotherapeutics have announced that approximately 3.1 million courses of its investigational oral antiviral COVID-19 treatment, molnupiravir, have ... Alongside the most recent US
The statement notes that while restrictions have been made on Regeneron and Lilly treatments at this time, there are still several therapy options, including Paxlovid, sotrovimab, Veklury (remdesivir) and molnupiravir, that
The FDA looks set to authorise Merck’s molnupiravir after its advisory body recommended the antiviral treatment, while Pfizer’s Paxlovid may be next. ... Oral medications like molnupiravir and Paxlovid are significantly more convenient than the
Merck’s Lagevrio (molnupiravir) -3CL protease inhibitor, approved in the UK last week, was originally developed to treat influenza.
The approval is based on results from the phase 3 MOVe-OUT clinical trial, which showed that molnupiravir reduced the risk of hospitalisation or death by approximately 50% against placebo. ... The US government has already placed an order for1.7 million
If approved, molnupiravir would be the first oral antiviral for use against COVID-19 in Europe. ... An interim analysis showed that molnupiravir reduced the risk of hospitalisation or death by approximately 50% against placebo.
More from news
Approximately 3 fully matching, plus 13 partially matching documents found.
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...